Baseline and screening visit characteristics
| Variable at baseline | Total (n=309) |
| Years at screening | |
| Mean (SD) | 61.9 (7.23) |
| Family history | |
| No | 267 (86%) |
| Yes | 41 (13%) |
| Missing | 1 (0%) |
| Charlson Comorbidities Index | |
| 1–2 | 229 (74%) |
| 3–4 | 77 (25%) |
| +5 | 3 (1%) |
| PSA, Median (IQR), ng/mL | 1.2 (0.7–2.2) |
| Prostate volume, Median (IQR), mL | 29 (23–28) |
| PSA density, Median (IQR), ng/mL2 | 0.04 (0.03–0.06) |
| Screening MRI positive | 48 (16%) |
| PSA density positive | 16 (5%) |
| Screening visit negative | 239 (77%) |
| Visit not completed | 6 (2%) |
PSA, prostate-specific antigen.